We analysed efficacy in the intention-to-treat population and safety in randomly assigned patients receiving at least one study dose. The final analysis is reported. This study is registered withClinicalTrials.gov, numberNCT00692770 .
Book Title: Adjuvant Sorafenib for Hepatocellular Carcinoma After Resection Or Ablation (STORM): a Phase 3, Randomised, Double-blind, Placebo-controlled Trial
Author:
Published on 2015 by
ISBN: /
Total Page:
Book Category:
Book is About: Carcinoma
Download Adjuvant Sorafenib for Hepatocellular Carcinoma After Resection Or Ablation (STORM): a Phase 3, Randomised, Double-blind, Placebo-controlled Trial eBook
Background: There is no standard of care for adjuvant therapy for patients with hepatocellular carcinoma. This trial was designed to assess the efficacy and safety of sorafenib versus placebo as adjuvant therapy in patients with hepatocellular carcinoma after surgical resection or local ablation. Methods: We undertook this phase 3, double-blind, placebo-controlled study of patients with hepatocellular carcinoma with a complete radiological response after surgical resection (n=900) or local ablation (n=214) in 202 sites (hospitals and research centres) in 28 countries. Patients were randomly assigned (1:1) to receive 400 mg oral sorafenib or placebo twice a day, for a maximum of 4 years, according to a block randomisation scheme (block size of four) using an interactive voice-response system. Patients were stratified by curative treatment, geography, Child-Pugh status, and recurrence risk. The primary outcome was recurrence-free survival assessed after database cut-off on Nov 29, 2013. We analysed efficacy in the intention-to-treat population and safety in randomly assigned patients receiving at least one study dose. The final analysis is reported. This study is registered withClinicalTrials.gov, numberNCT00692770 . Findings: We screened 1602 patients between Aug 15, 2008, and Nov 17, 2010, and randomly assigned 1114 patients. Of 556 patients in the sorafenib group, 553 (\u003e99%) received the study treatment and 471 (85%) terminated treatment. Of 558 patients in the placebo group, 554 (99%) received the study treatment and 447 (80%) terminated treatment. Median duration of treatment and mean daily dose were 12·5 months (IQR 2·6–35·8) and 577 mg per day (SD 212·8) for sorafenib, compared with 22·2 months (8·1–38·8) and 778·0 mg per day (79·8) for placebo. Dose modification was reported for 497 (89%) of 559 patients in the sorafenib group and 206 (38%) of 548 patients in the placebo group. At final analysis, 464 recurrence-free survival events had occurred (270 in the placebo group and 194 in the sorafenib group). Median follow-up for recurrence-free survival was 8·5 months (IQR 2·9–19·5) in the sorafenib group and 8·4 months (2·9–19·8) in the placebo group. We noted no difference in median recurrence-free survival between the two groups (33·3 months in the sorafenib group vs 33·7 months in the placebo group; hazard ratio [HR] 0·940; 95% CI 0·780–1·134; one-sided p=0·26). The most common grade 3 or 4 adverse events were hand-foot skin reaction (154 [28%] of 559 patients in the sorafenib group vs four [
Our website offers free Carcinoma Ebooks to download. Adjuvant Sorafenib for Hepatocellular Carcinoma After Resection Or Ablation (STORM): a Phase 3, Randomised, Double-blind, Placebo-controlled Trial is the one of great book to have from us, a free ebooks portal, the best free ebooks download library. You can find and download free ebooks in categories. No registration is required to download free e-books. We have huge collection of Carcinoma and ebooks. Each downloadable ebook has a short review with a description. You can find over thousand of ebooks that are free to download. Get ton of books with us, the open directory for free ebooks and download links, the best place to read ebooks and search free download ebooks.Carcinoma ebooks free
download Adjuvant Sorafenib for Hepatocellular Carcinoma After Resection Or Ablation (STORM): a Phase 3, Randomised, Double-blind, Placebo-controlled Trial ebook as PDF, EPUB, MOBI, AZW and AZW3, FB2, DJVU, LIT, RFT, IBA, LRS, LRF, and LRX.
download ebooks
There are so many ebooks about Adjuvant Sorafenib for Hepatocellular Carcinoma After Resection Or Ablation (STORM): a Phase 3, Randomised, Double-blind, Placebo-controlled Trial that are available to have. Thinking of having Adjuvant Sorafenib for Hepatocellular Carcinoma After Resection Or Ablation (STORM): a Phase 3, Randomised, Double-blind, Placebo-controlled Trial ebook? You are in the right place. Get the ebook Adjuvant Sorafenib for Hepatocellular Carcinoma After Resection Or Ablation (STORM): a Phase 3, Randomised, Double-blind, Placebo-controlled Trial by: .
Book Details:
- Book was ranked at 22 by Google Books for Adjuvant Sorafenib for Hepatocellular Carcinoma After Resection Or Ablation (STORM): a Phase 3, Randomised, Double-blind, Placebo-controlled Trial
- Adjuvant Sorafenib for Hepatocellular Carcinoma After Resection Or Ablation (STORM): a Phase 3, Randomised, Double-blind, Placebo-controlled Trial published by since 2015 with ISBNs. The book ISBN 13 Code is and ISBN 10 Code is
- Reading Mode in Text Status is false and Reading Mode in Image Status is false
- The book has " Pages" is Printed at BOOK under Category
- Rated by Raters and have average rate at ""
- eBook written in en
- Book Preview Address: http://books.google.com/books?id=R83AvQEACAAJ&dq=Carcinoma&hl=&cd=301&source=gbs_api
Book Preview
The Button is not working? Try The Alternative links for "Adjuvant Sorafenib for Hepatocellular Carcinoma After Resection Or Ablation (STORM): a Phase 3, Randomised, Double-blind, Placebo-controlled Trial by: ":
- Server 2: SECURE LINK